16 years ago

Myconostica Secures £1.7 Million in Series D Funding

  • Myconostica, a UK-based medical diagnostics company, has secured £1.7 million in the first close of its Series D funding round

  • The company focuses on developing rapid, point-of-care molecular diagnostics for infectious diseases, enabling fast and accurate diagnosis for timely treatment and infection control.

      • ProblemHealthcare

      "Lab testing for infectious diseases is slow and unreliable. Waiting days or weeks for results can delay treatment and spread of infection. "

      Solution

      "Myconostica provides rapid, accurate, and affordable lab testing for infectious diseases using its proprietary technology. This enables faster diagnosis and treatment of patients, reducing healthcare costs and improving patient outcomes."

      Covered on